Castle Biosciences
Presença
Castle Biosciences é uma das ...
Castle Biosciences é uma empresa listada sob o símbolo CSTL (US).
Executivos
Veja o organograma con seus 31 executivos principais
Biografias mais buscadas da Castle Biosciences
- Derek Maetzold, Director, President and Chief Executive Officer
- Mara Aspinall, Director
- Miles Harrison, Director
Recentes movimentos de executivos em Castle Biosciences
- Rodney Cotton, ingressou na Companhia como Director (Notícia publicada em 29 de março de 2024).
Criar um alerta
para seguir os movimentos de executivos da Castle Biosciences.
Biotecnologia
Castle Biosciences possui 2.279 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Metsera acaba de anunciar uma arrecadação de fundos de 290 milhões de dólares. (publicado em 23 de abril de 2024).
- Histogen has filed for bankruptcy protection (publicado em 19 de abril de 2024).
- Bruker has announced the acquisition of NanoString Technologies (publicado em 18 de abril de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Castle Biosciences
- Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
- Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
- Castle Biosciences Announces Updates to its Board of Directors
- Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
- In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
- Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
- Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
- New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
- Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
- View more press releases Close
Redes sociais sobre Castle Biosciences
- Castle Biosciences na Wikipedia, Google News e Yahoo Finance
- Castle Biosciences na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Derek Maetzold 
Ligue para a Castle Biosciences em +1 866...
